Elevated expression of SIGLEC8 in skin cutaneous melanoma predicts better prognosis associated with hematopoietic cell lineage pathway

High SIGLEC8 expression predicts longer survival in SKCM. We propose that SIGLEC8 boosts antitumor immunity by influencing B‑cell and T‑cell pathways (including FCER2, CR2, MS4A1, and CD8A/B) in the tumor microenvironment. SIGLEC8 thus shows promise as a low‑cost prognostic biomarker and a potential therapeutic target. Table S1 shows cancer-type-specific prognostic effects for SIGLEC8: in SKCM higher SIGLEC8 expression associates with improved survival, whereas prognostic directionality varies across other tumor types. A pan-cancer comparison revealed cancer-type-specific prognostic effects for SIGLEC8: in SKCM higher SIGLEC8 expression associates with improved survival, whereas prognostic directionality varies across other tumor types.